Medical

The US FDA has approved Elacestrant, the first oral selective estrogen receptor degrader (SERD), for the treatment of patients with advanced or metastatic breast cancer who are estrogen receptor positive, HER2 negative and have an ESR1 mutation. Results of the trial showed that patients treated with Elacestrant had a 45% reduction in the risk of disease progression or death.

The development of an effective anti-aging drug and functional food to slow down ASCs' aging is crucial

As medicine continues to advance, there are many good drugs and options to fight cancer. Just recently, a study showed that the NALIRIFOX regimen significantly improved the overall survival of patients with advanced pancreatic ductal adenocarcinoma who had not received previous treatment.

CAR-T therapy is a cellular immunotherapy treatment that has become very popular in recent years. This therapy uses genetic engineering techniques to upgrade the patient's immune T cells in vitro, before entering the body to exert a powerful anti-cancer effect. Currently, CAR-T therapy has performed very well in blood cancers such as lymphoma and leukaemia.

The pursuit of eternal beauty is the dream of every woman. For thousands of years, many people have made unremitting efforts to achieve the goal of beauty, so many stories about beauty have emerged.

With the continuous development of science and technology, a series of new myopia correction operations have emerged in the field of ophthalmology. After surgery, myopia patients can also achieve the vision effect when wearing glasses without wearing glasses. Excimer laser surgery, which has been carried out in the last two decades, has the advantages of high efficiency, accuracy and safety.

Science has published two consecutive research articles that suggest new ways to improve the efficacy of CAR-T for solid tumours.

For patients with relapsed and refractory multiple myeloma, the CAR-T cell therapy Ide-cel resulted in a two-fold increase in the average length of time that patients' tumours did not progress compared to standard treatment, with 71% of patients experiencing substantial tumour regression and 39% experiencing complete tumour disappearance.

Researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have now identified a new treatment that promises to help cancer patients with bone marrow transplants manage side effects better than current standard therapies, making the treatment more effective and safer.

Who is CinCor?